BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Toripalimab: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: RemeGen Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., LaNova Medicines Limited, Suzhou Abogen Biosciences Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-30 est. | P1/P2 | Suzhou Abogen Biosciences Co., Ltd. | NCT06088004 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | Solid Tumor, Adult | recruiting | 218 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2026-12-31 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06079112 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | recruiting | 100 |
| 2027-01-11 est. | P1/P2 | LaNova Medicines Limited | NCT05615974 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | Malignant Tumors | recruiting | 139 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P1/P2 | LaNova Medicines Limited | NCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 392 |
| 2026-10-01 est. | P2 | RemeGen Co., Ltd. | NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | Breast Cancer | recruiting | 40 |
| 2026-06 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06823427 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Urothelial Carci | recruiting | 60 |
| 2026-06 est. | P2 | RemeGen Co., Ltd. | NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | Breast Cancer | recruiting | 40 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.